Sage 'en­cour­aged' by ini­tial Zurzu­vae sales in post­par­tum de­pres­sion, but no word on ma­jor de­pres­sion plans

Doc­tors or­dered 120 pre­scrip­tions of Zurzu­vae, the new pill for post­par­tum de­pres­sion, in the fi­nal days of De­cem­ber once the drug be­came avail­able, its man­u­fac­tur­er Sage Ther­a­peu­tics an­nounced Wednes­day.

The high­ly-an­tic­i­pat­ed pill — the first ever for a form of de­pres­sion that af­fects 500,000 moth­ers in the US each year — is al­ready on track to beat sales of its pre­de­ces­sor Zul­res­so, an oner­ous in­fu­sion that re­quired a three-day hos­pi­tal stay. Pre­scrip­tions of Zurzu­vae, in con­trast, are be­ing de­liv­ered di­rect­ly to pa­tients’ homes, the com­pa­ny said. But Sage didn’t pro­vide an up­date on the pill’s un­cer­tain fu­ture as a po­ten­tial treat­ment for ma­jor de­pres­sion, a big­ger and more lu­cra­tive mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER